Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
<h4>Background</h4> <p>Psoriatic arthritis (PsA) recommendations state that the target of treatment should be remission or Low disease activity (LDA). We used a real life dataset to compare different potential targets.</p> <h4>Methods</h4> <p>250 PsA patien...
Váldodahkkit: | van Mens, L, van de Sande, M, van Kuijk, A, Baeten, D, Coates, L |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
BMJ Publishing Group
2017
|
Geahča maid
-
Considerations for the definition of remission criteria in psoriatic arthritis
Dahkki: Mease, P, et al.
Almmustuhtton: (2017) -
Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice
Dahkki: Leonieke J. J. van Mens, et al.
Almmustuhtton: (2017-10-01) -
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
Dahkki: Henriëtte M. Y. de Jong, et al.
Almmustuhtton: (2019-09-01) -
Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need use CRP?’ by Gonçalves et al.
Dahkki: Van Mens, L, et al.
Almmustuhtton: (2019) -
Remission in psoriatic arthritis—where are we now?
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)